Pancreatic Interception/High-Risk Cohorts Dream Team - Stand Up to Cancer
Help save a life

This holiday season, Mastercard is standing with us in the fight to end cancer as we know it. From now until December 31st, 2018, if you use a Mastercard to donate to Stand Up To Cancer, Mastercard will TRIPLE your gift, up to $300,000!

That’s triple the impact to support groundbreaking cancer research that will help save lives now!

$25 = $75
$50 = $150
$100 = $300
$250 = $750
GIVE FOR LIFE
For every $1 donated through StandUpToCancer.org with a Mastercard, Mastercard will donate $2, up to $300,000. Offer starts 12/14/18 at 12:01am ET and ends 12/31/18 at 11:59pm ET, or at the $300,000 max, whichever comes first.

Dream Teams

Research  >  Research Portfolio  >  Dream Teams  >  Pancreatic Interception/High-Risk Cohorts Dream Team

SU2C–Lustgarten Foundation Pancreatic Cancer Interception Dream Team:
Intercepting Pancreatic Cancer in High-Risk Cohorts

Grant Term: February 2018–January 2022

The SU2C–Lustgarten Foundation Pancreatic Cancer Interception Dream Team’s goal is to intercept pancreatic cancer in high-risk patients through careful early detection and targeted immune prevention. Working first with relatives of people with pancreatic cancer, this team seeks to create a test to screen people at risk for pancreatic cancer to potentially detect the cancer earlier and offer the most effective treatment options to patients.

ABOUT THIS TEAM’S RESEARCH

Currently there is no suitable screening test for pancreatic cancer. The goal of the SU2C–Lustgarten Foundation Pancreatic Cancer Interception Dream Team is to actively block pancreatic cancer at its earliest stages in patients at high risk.

The team is testing 2,000 pancreatic cancer patients for genetic mutations and screening the immediate family members of mutation carriers for their own pancreatic cancer risk. Cancer-free relatives who carry a mutation are being invited to enter an active screening protocol, tied to computer-based “deep learning” imaging that can detect cancers too small to be seen by the human eye. A subset of high-risk individuals who are currently cancer-free but have precancerous lesions in their pancreas are being invited to participate in the first-ever clinical trial of a vaccine to prevent pancreatic cancer.

Finally, the team is developing a “blood test” for very early diagnosis of pancreatic cancer, to be applied to people at high risk, such as those with new-onset diabetes.

This Dream Team is part of the SU2C Cancer Interception Initiative, an approach that looks for ways to actively intervene in the formation of the disease rather than treating it only after it is fully developed, and is part of the Pancreatic Cancer Collective portfolio of research.

MEET THE TEAM

The top scientists and researchers on the SU2C–Lustgarten Foundation Pancreatic Cancer Interception Dream Team come from a variety of backgrounds and disciplines, which leads them to great insights upon collaboration. Learn more about the SU2C–Lustgarten Foundation Pancreatic Cancer Interception Dream Team.

Team Members

Anirban Maitra, MBBS
University of Texas
MD Anderson Cancer Center
Team Leader

Michael G. Goggins, MD
Johns Hopkins University
Co-leader

Scott M. Lippman, MD
University of California, San Diego
Co-leader

Tyler Jacks, PhD
Massachusetts Institute of Technology
Principal Investigator

Gloria Peterson, PhD
Mayo Clinic
Principal Investigator

Sapna Syngal, MD, MPH
Dana-Farber Cancer Institute
Principal Investigator

Barbara Kenner
Kenner Family Research Fund
Advocate

Scott Nelson
Advocate

Bettina Marble
University of Texas
MD Anderson Cancer Center
Project Manager

Pamela Constantinou Papadopoulos, PhD
University of Texas
MD Anderson Cancer Center
Project Manager

“By focusing on individuals at high risk of pancreatic cancer, we hope to intercept the disease process at a very early stage when it can be more successfully treated, and thus save many lives.”

Anirban Maitra, MBBS
University of Texas
MD Anderson Cancer Center

TEAM PROGRESS UPDATES

Stand Up To Cancer’s research projects are designed to foster collaborative, swift translational research. The hallmarks of these efforts include rigorous application and selection procedures, sufficient funding to allow scientists to focus on the objectives of the grant, and reviews by senior scientists every six months. These reviews help the investigators capitalize on the latest findings, address potential roadblocks, and collaboratively evolve as the science requires. Please click the button below to see summaries of research results so far for the SU2C–Lustgarten Foundation Pancreatic Cancer Interception Dream Team.

TEAM PROGRESS UPDATES

PUBLICATIONS

This team started its work in November 2017; links to publications will be posted when they are available.

CLINICAL TRIALS REFERRALS

Cancer clinical trials allow researchers to study innovative and potentially life-saving new treatments. The goal is to find treatments that are better than what’s currently available; in fact, the therapies offered to today’s cancer patients were almost all studied and made possible by people participating in clinical trials. But many cancer clinical trials aren’t completed because not enough people take part.

At StandUpToCancer.org/ClinicalTrials, you’ll find information and answers to common questions about clinical trials. Learn more and talk to your doctor to see if a clinical trial may be the best choice for you.

You can also connect with EmergingMed, a free and confidential clinical trial matching service that provides access to a vast database to help you identify the clinical trials that might be right for you or your loved one.

LEARN MORE